IP Library Patent Application 13767692
Patent Application
App. No. 13/767,692

METHODS AND SYSTEMS FOR BUFFERING SOLUTIONS WITH CONTROLLED TONICITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/767,692
Abstract

An anesthetic cartridge is adapted to receive a volume of buffer by displacing a plunger in one end of the anesthetic cartridge inwardly so that addition of the buffer volume will not displace the plunger excessively beyond the end of the cartridge body. The inwardly displaced end is protected by a plug or cover which prevents contamination and which is ejected when the buffer is added. The amount of buffer volume injected is selected to raise the pH of the anesthetic to a target value and to simultaneously achieve a target tonicity.

Claims (35)

1 . A liquid medicament cartridge comprising:

a hollow body having a first open end and a second open end;

a needle-penetrable septum over the first open end;

a plunger spaced inwardly from the second open end; and

a protective plug inserted into the second open end, said protective plug being displaceable as additional liquid is injected through the septum into the hollow body to cause the plunger to move toward the plug.

2 . A medicament cartridge as in claim 1 , wherein the hollow body comprises a glass tube.

3 . A medicament cartridge as in claim 1 , wherein the protective plug has a distal end which engages the plunger and a proximal end which covers the second opening to maintain sterility.

4 . A medicament cartridge as in claim 3 , wherein the proximal end of the plug is configured so that it cannot be pushed into the second open end of the hollow body to prevent premature inward displacement of the plunger.

5 . A medical cartridge as in claim 3 , wherein the proximal end of the plug is configured so that it is difficult to manually grasp when present over the second open end of the hollow body and easier to grasp when displaced proximally from the second open end.

6 . A method for buffering anesthetic carried in a container, said method comprising:

injecting a buffer into the container to outwardly displace a plunger which in turn ejects a protective plug which covers the plunger.

7 . A method as in claim 6 , wherein the protective plug prevents contamination of the cartridge prior to ejection.

8 . A method as in claim 6 , wherein the protective plug prevents inward displacement of the plunger prior to ejection.

9 . A method as in claim 6 , wherein the plunger is configured so that it cannot be pushed into the container.

10 . A method for buffering a liquid anesthetic having a target tonicity and a target pH, said method comprising:

providing a volume of the liquid anesthetic in a sealed container having a septum at one end and a plunger at an opposite end, wherein the anesthetic is initially acidic; and

injecting a volume of buffer through the septum into the anesthetic;

wherein the buffer is hypertonic and has a basic pH selected so that the buffered anesthetic will have both the target pH and the target tonicity.

11 . A method as in claim 10 , wherein the target tonicity is less than 500 mOsm/kg.

12 . A method as in claim 10 , wherein the target tonicity is less than 400 mOsm/kg.

13 . A method as in claim 10 , wherein the target tonicity is substantially isotonic.

14 . A method as in claim 10 , wherein the anesthetic originally has a pH below 6.0 and the volume of buffer raises the pH of the buffered anesthetic to a target pH of at least 7.0.

15 . A method as in claim 14 , wherein the volume of buffer increases the pH to a target pH of at least 7.3.

16 . A method as in claim 10 , wherein the buffer comprises hypertonic sodium chloride.

17 . A method as in claim 10 , wherein the anesthetic further comprises a vasoconstrictor

18 . A method as in claim 17 , wherein the vasoconstrictor comprises epinephrine.

19 . A method as in claim 10 , wherein the buffer comprises sodium bicarbonate.

20 . A method as in claim 10 , wherein the cartridge is prepared at a central manufacturing facility and the cartridges are distributed to a plurality of local users, wherein the users inject the buffer.

21 . A method as in claim 20 , wherein the users inject the buffer prior to a procedure, in order to produce buffered anesthetic for use in the procedure.

22 . A method as in claim 21 , wherein at least a portion of the buffered anesthetic is injected into a patient within 2 minutes of introducing the buffer.

23 . A method as in claim 10 , wherein the local anesthetic is an amide local anesthetic.

24 . A method as in claim 10 , wherein the local anesthetic is an amine local anesthetic.

25 . A method as in claim 10 , wherein the local anesthetic is lidocaine.

26 . A method as in claim 10 , wherein the local anesthetic is articaine.

27 . A method as in claim 10 , wherein an internal volume of the anesthetic cartridge is in the range from 1.45 ml to 2.3 ml, the anesthetic volume is in the range from 1.15 ml to 2.2 ml, and the buffer volume is in the range from 0.1 ml to 0.35 ml.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Dec 3, 2014
From: ONPHARMA INC
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 034524/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2014
From: STEPOVICH, MATTHEW J.; FALKEL, MICHAEL I.; FOLEY, MARK
To: ONPHARMA, INC.
Reel/Frame 033275/0963 →